Ignite Creation Date:
2025-12-24 @ 7:13 PM
Ignite Modification Date:
2026-01-02 @ 5:29 PM
Study NCT ID:
NCT03028103
Status:
COMPLETED
Last Update Posted:
2023-06-26
First Post:
2016-12-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Sponsor:
Epizyme, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-03-27
Start Date Type:
ACTUAL
Primary Completion Date:
2019-10-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-11-29
Completion Date Type:
ACTUAL
First Submit Date:
2016-12-19
First Submit QC Date:
None
Study First Post Date:
2017-01-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-12-07
Results First Submit QC Date:
None
Results First Post Date:
2021-04-19
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-06-23
Last Update Post Date:
2023-06-26
Last Update Post Date Type:
ACTUAL